0001209191-16-111003.txt : 20160330
0001209191-16-111003.hdr.sgml : 20160330
20160330130715
ACCESSION NUMBER: 0001209191-16-111003
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160329
FILED AS OF DATE: 20160330
DATE AS OF CHANGE: 20160330
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Corvus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001626971
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464670809
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: (650) 900-4520
MAIL ADDRESS:
STREET 1: 863 MITTEN ROAD
STREET 2: SUITE 102
CITY: BURLINGAME
STATE: CA
ZIP: 94010
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37719
FILM NUMBER: 161538322
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-03-29
0
0001626971
Corvus Pharmaceuticals, Inc.
CRVS
0001388325
Novo A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
Common Stock
2016-03-29
4
C
0
2130492
A
2130492
D
Common Stock
2016-03-29
4
C
0
356888
A
2487380
D
Common Stock
2016-03-29
4
P
0
666666
15.00
A
3154046
D
Series A Preferred Stock
2016-03-29
4
C
0
2130492
0.00
D
Common Stock
2130492
0
D
Series B Preferred Stock
2016-03-29
4
C
0
356888
0.00
D
Common Stock
356888
0
D
The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") had no expiration date. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.
Represents a purchase from the underwriters in the Issuer's public offering.
Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), which is currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Thomas Dyrberg, Chief Executive Officer, Novo A/S
2016-03-30